2022
Abstract 3379: Multi-cohort study shows HCC is associated with a relative regional reduction in TGFBR2 in liver biopsies from patients with cirrhosis
Bhowmick K, Amdur R, Xiang X, Yu H, Wong L, Rao S, He A, Amin K, Zaheer D, Narayan R, Satapathy S, Guha C, Latham P, Shetty K, Gough N, Mishra L. Abstract 3379: Multi-cohort study shows HCC is associated with a relative regional reduction in TGFBR2 in liver biopsies from patients with cirrhosis. Cancer Research 2022, 82: 3379-3379. DOI: 10.1158/1538-7445.am2022-3379.Peer-Reviewed Original ResearchHepatocellular carcinomaLiver biopsyCirrhotic tissueStaining intensityAmerican Association for Cancer Research annual meetingsLogistic regression modelsDetection of hepatocellular carcinomaDiagnostic of hepatocellular carcinomaEarly detection of hepatocellular carcinomaMulti-cohort studyEvaluating biopsy samplesAnalysis of biopsy tissueAssociated with hepatocellular carcinomaTransforming growth factor-bDevelopment of hepatocellular carcinomaIndependent patient cohortHigh-risk groupGrowth factor BQuantitative IHCPatient cohortBiopsy tissueBiopsy samplesClinical trialsCirrhosisLoss of function
2010
Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk
Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2010, 73: 138-146. PMID: 21195504, DOI: 10.1016/j.lungcan.2010.11.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDNA RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedPolymorphism, GeneticRisk FactorsSmokingXeroderma Pigmentosum Group A ProteinXeroderma Pigmentosum Group D ProteinYoung AdultConceptsNon-small cell lung cancerLung cancer riskSquamous cell carcinomaLung cancerCancer riskCell carcinomaSingle nucleotide polymorphismsHigh riskGenetic polymorphismsNon-small cell lung cancer riskRisk of NSCLCCell lung cancer riskHigher lung cancer riskCell lung cancerVariant AA genotypeDominant risk factorNumerous epidemiological studiesLogistic regression modelsDNA repair pathway genesYoung smokersNSCLC casesSubgroup analysisRisk factorsHealthy controlsStratified analysis
2003
Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics.
Dai Q, Franke A, Yu H, Shu X, Jin F, Hebert J, Custer L, Gao Y, Zheng W. Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiology Biomarkers & Prevention 2003, 12: 497-502. PMID: 12814993.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAnthropometryBiomarkers, TumorBody Mass IndexBody WeightBreast NeoplasmsCase-Control StudiesChinaDehydroepiandrosterone SulfateEatingEstrogensFemaleFibroadenomaHumansIsoflavonesMenopauseMiddle AgedPhytoestrogensPlant PreparationsRisk FactorsSex Hormone-Binding GlobulinStatistics as TopicTestosteroneWomen's HealthConceptsBody mass indexBreast cancer riskUrinary phytoestrogen excretionSteroid sex hormonesSex hormonesCancer riskSteroid hormonesUrinary isoflavonoidsBlood levelsInverse associationBreast cancerExcretion rateEndogenous steroid sex hormonesHigher body mass indexMammalian lignansConditional logistic regression modelsPotential confounding factorsHigh blood concentrationsCase-control pairsPotential protective associationLogistic regression modelsPostmenopausal womenMorning bloodMass indexHip ratio
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigenDetection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918.. DOI: 10.1097/00005392-199703000-00047.Peer-Reviewed Original ResearchProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseMicro g.Clinicopathological featuresSurgical marginsRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesUnivariate logistic regression modelYear of surgerySubset of patientsLength of followup